KRAS wild-type pancreatic ductal adenocarcinoma

What changed: KRAS wild-type pancreatic ductal adenocarcinoma

Every dated change on the records linked to KRAS wild-type pancreatic ductal adenocarcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Trial result1Milestone6This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-18This recordKRAS wild-type pancreatic ductal adenocarcinoma
Facts on this page last checked
When this page itself was last checked or edited.

2024 · 1

2024MilestoneZenocutuzumab
Zenocutuzumab approved for NRG1 fusion-positive pancreatic cancer
A milestone in how this cancer is treated.

2023 · 2

2022 · 1

2022MilestoneDabrafenib + trametinib
Dabrafenib plus trametinib approved for BRAF V600E solid tumours regardless of site
A milestone in how this cancer is treated.

2018 · 2

2015 · 1

2015MilestoneComprehensive genomic profiling
Sequencing studies show that KRAS wild-type pancreatic cancers are enriched for alternative drivers
A milestone in how this cancer is treated.